It's a microcap pharma stock in R&D. All of them have that in their filing. The have a capital access agreement they are pulling from as needed.
Insiders didn't technically buy. They received it as compensation. They probably see the value in the Amiket deal that's supposed to be finalized next month
News 
Market Data 
Discover 
